Every number here carries a trial name, a dose and a week. Where the evidence is thin we say so in the first sentence, not in a footnote. Where it does not exist we say that too.
Brand is not molecule. Semaglutide is sold as three brands and tirzepatide as two, and they differ by what they are licensed for, not by what is in them. Every approved name in one place, plus a table that puts all nine side by side.
See the comparison table →
Sub-label GLP-1 dosing: what the term means, what the dose-response data actually shows, and where the evidence stops.
Retatrutide, cagrilintide, orforglipron and the grey market. Evidence tier and legal status for each, stated plainly.
Points programs, fasting protocols, supplements and training. Honest effect sizes, including when the honest answer is "not much".
Training, running, sleep, heart rate, diabetes, alcohol. What changes on a GLP-1 and what to watch for.
Evidence updates
Approvals move, trials read out, labels get rewritten. We re-check these pages against their primary sources and email what actually changed, with the citation next to it.
What you will not get: protocols, supplement offers, "wellness" or a drip sequence. If a month goes by and nothing worth sending has changed, we do not send anything.
Confirmed by email before anything is sent, so a typo cannot sign up a stranger. One-click unsubscribe in every message. The list is never shared or sold.